Idioma:

Cell factories for insulin production

Baeshen, Nabih A ; Baeshen, Mohammed N ; Sheikh, Abdullah ; Bora, Roop S ; Ahmed, Mohamed Morsi M ; Ramadan, Hassan A I ; Saini, Kulvinder Singh ; Redwan, Elrashdy M

Microbial cell factories, 2014-10, Vol.13 (1), p.141-141, Article 141 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cell factories for insulin production
Autor: Baeshen, Nabih A ; Baeshen, Mohammed N ; Sheikh, Abdullah ; Bora, Roop S ; Ahmed, Mohamed Morsi M ; Ramadan, Hassan A I ; Saini, Kulvinder Singh ; Redwan, Elrashdy M
Assuntos: Amino acids ; Biotechnology ; Diabetes ; Diabetics ; Drug dosages ; E coli ; Escherichia coli ; Escherichia coli - genetics ; Escherichia coli - metabolism ; Factories ; FDA approval ; Gene expression ; Genetic engineering ; Genetically modified plants ; Growth hormones ; Health aspects ; Humans ; Insulin ; Insulin resistance ; Molecular weight ; Pharmaceutical industry ; Plants, Genetically Modified - genetics ; Plants, Genetically Modified - metabolism ; Polypeptides ; Production capacity ; Proinsulin - biosynthesis ; Proinsulin - genetics ; Proteins ; Recombinant proteins ; Recombinant Proteins - biosynthesis ; Recombinant Proteins - genetics ; Review ; Saccharomyces cerevisiae ; Saccharomyces cerevisiae - genetics ; Saccharomyces cerevisiae - metabolism ; Seeds ; Tobacco ; Transgenic animals ; Yeast
É parte de: Microbial cell factories, 2014-10, Vol.13 (1), p.141-141, Article 141
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
Descrição: The rapid increase in the number of diabetic patients globally and exploration of alternate insulin delivery methods such as inhalation or oral route that rely on higher doses, is bound to escalate the demand for recombinant insulin in near future. Current manufacturing technologies would be unable to meet the growing demand of affordable insulin due to limitation in production capacity and high production cost. Manufacturing of therapeutic recombinant proteins require an appropriate host organism with efficient machinery for posttranslational modifications and protein refolding. Recombinant human insulin has been produced predominantly using E. coli and Saccharomyces cerevisiae for therapeutic use in human. We would focus in this review, on various approaches that can be exploited to increase the production of a biologically active insulin and its analogues in E. coli and yeast. Transgenic plants are also very attractive expression system, which can be exploited to produce insulin in large quantities for therapeutic use in human. Plant-based expression system hold tremendous potential for high-capacity production of insulin in very cost-effective manner. Very high level of expression of biologically active proinsulin in seeds or leaves with long-term stability, offers a low-cost technology for both injectable as well as oral delivery of proinsulin.
Editor: England: BioMed Central Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Cell factories for insulin production

Baeshen, Nabih A ; Baeshen, Mohammed N ; Sheikh, Abdullah ; Bora, Roop S ; Ahmed, Mohamed Morsi M ; Ramadan, Hassan A I ; Saini, Kulvinder Singh ; Redwan, Elrashdy M

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.